Controlled-ileal-release nicotinic acid (CIR-NA) is a special form of nicotinic acid (also known as niacin or vitamin B3) that is designed to be released in a controlled manner in the small intestine. This medication is being studied for its potential to help people with prediabetes. The controlled release formulation is designed to minimize side effects while maintaining the therapeutic benefits. Nicotinic acid may help regulate blood sugar levels and improve insulin sensitivity.

Placebo is an inactive substance that looks identical to the real medication but contains no active ingredients. It is used as a comparison to determine if the actual medication is effective.

Prediabetes – A condition where blood sugar levels are higher than normal but not high enough to be diagnosed as type 2 diabetes. It occurs when cells become resistant to insulin or when the pancreas doesn’t produce enough insulin to maintain normal blood glucose levels. People with prediabetes often have no clear symptoms, and the condition develops gradually. Prediabetes affects the body’s ability to process sugar (glucose) properly. Without intervention, prediabetes can progress to type 2 diabetes over time.

Type 2 Diabetes Mellitus – A chronic metabolic disorder characterized by high blood sugar levels due to the body’s ineffective use of insulin. The condition develops when the body becomes resistant to insulin or doesn’t produce enough insulin to maintain normal glucose levels. It typically develops gradually, and the body becomes increasingly unable to process sugar properly. The condition affects how the body metabolizes glucose, which is vital for energy production in cells.